cell therapy

MS cell-based therapy PTG-007 wins patent protection in China

Poltreg will receive a patent in China that covers the administration of its cell-based therapy PTG-007 for multiple sclerosis (MS) via an injection into the spinal canal, or intrathecally. The method showed superior benefits compared with PTG-007’s intravenous infusion into the bloodstream in a Phase 1b/2a study of people…

KYV-101 helps 2 hard-to-treat progressive MS patients: Case study

Kyverna Therapeutics‘ cell-based therapy KYV-101 had an acceptable safety profile and promising treatment effects when given to two people with hard-to-treat progressive multiple sclerosis (MS), according to a case study. “We are very pleased about offering this potentially paradigm-shifting treatment opportunity to patients that have exhausted other medical…

ATA188 fails to outperform placebo in EMBOLD clinical trial

ATA188, an experimental cell therapy targeting the Epstein-Barr virus, failed to outperform a placebo at easing disability levels in people with nonactive progressive forms of multiple sclerosis (MS), according to data from the Phase 2 portion of the EMBOLD clinical trial. The medication also showed no signs of…

Novel CAR T-cell Therapy Shows Promise in MS Mouse Study

Researchers have developed a technique that uses CAR T-cells, a form of cell therapy, to specifically eliminate the self-reactive immune cells that drive multiple sclerosis (MS), without destroying healthy immune cells needed to protect against infection. “Our CAR-T cells were very effective at treating mice that have an MS-like…

Q Therapeutics Approved to Start Trial of Cell Therapy Aiming to Restore Myelin

A cell therapy intended to boostĀ myelin regeneration ā€” Q-Cells byĀ Q TherapeuticsĀ ā€”Ā has received aĀ green light from the U.S. Food and Drug Administration to proceed with a clinical trial in patients with transverse myelitis (TM), a disease that likeĀ multiple sclerosis is characterized by myelin damage. FDA approval of the companyā€™s Investigational New…